| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.0077 | 0.9 |